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ing years per 1,000 patients. Predicted UK-wide benefits included the avoidance of 
2,097 transplants, 994 access procedures, approximately 2.5 million haemodialysis 
sessions and more than 900,000 peritoneal dialysis days, with gains of 71,500 QALYs, 
78,800 life years and 86,045 working years. ConClusions: ADPKD-associated ESRD 
represents a significant burden to both patients and healthcare systems. Delaying 
disease progression through treatment could meaningfully impact this burden, 
reducing healthcare resource use, requirement for donor organs and the negative 
impact upon quality-of-life, life-expectancy and productivity.
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objeCtives: Cardiovascular deterioration and renal dysfunction are significant 
complications for some muscular dystrophy (MD) patients. Although MD patients 
with cardiovascular problems may benefit from ACE-inhibitor treatment, there 
is some debate about whether this therapy is safe for use in patients with renal 
dysfunction. The objective of this study was to describe ACE-inhibitor treatment 
among MD patients with severe renal dysfunction, as they may be the most likely 
candidates for contraindication. Methods: We identified two cohorts of individu-
als aged 0-64 with a muscular dystrophy diagnosis between 1/1/2009 and 10/31/2013 
or 1/01/2009 and 10/31/2011 from an administrative claims database. Patients were 
continuously enrolled with benefits for 12 and 36 months, respectively, after the 
index date, defined as the first date of evidence of severe renal dysfunction--chronic 
kidney disease, renal failure or end stage renal disease. Subsequent ACE-inhibitor 
use was evaluated in the 12 and 36 months after index date. Results: A total of 
11,515 MD patients with 12 months continuous enrollment, and 4,547 individuals 
with MD and 36 months continuous enrollment were identified, of which 14 -20% 
filled at least one prescription for an ACE-inhibitor. There were 340 (3%) patients 
with 12 months enrollment who had evidence of severe renal dysfunction, and 127 
(37%) of those filled a subsequent prescription for an ACE-inhibitor. There were 94 
(2%) patients with 36 months enrollment who had evidence of severe renal dys-
function, of which 50 (53%) filled at least one subsequent prescription for an ACE-
inhibitor. ConClusions: Cardio-protective treatment with ACE-inhibitors among 
MD patients is significant. Although severe renal dysfunction is not highly prevalent 
in this population, 36%-49% with the condition were treated with an ACE-inhibitor, 
despite a possible contraindication, especially in patients with severe disease. New 
therapies in development which address underlying disease rather than complica-
tions may enable patients to avoid potential contraindications.
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objeCtives: Fingolimod oral tablets were approved in the United States (US) in 
September 2010 for the treatment of relapsing remitting multiple sclerosis (RRMS). 
The objective of this study is to assess the costs associated with Fingolimod treat-
ment for patients diagnosed with RRMS in the US. Methods: A large US adminis-
trative retrospective claims database was used to identify patients diagnosed with 
RRMS and were prescribed Fingolimod between January 2010 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. Results: There were a total of 28,477 patients that met 
the study inclusion criteria. Patients on average were charged $5270.93 ± 2760.33 
for their treatment with Fingolimod during the study period. However, the allowed 
amount by the health plan was $4624.41 ± 2070.65 and the actual paid amount was 
$4529.98 ± 2074.58. On average, patient’s deductible was $13.64 ± 186.88 and patient 
co-payment was $86.33 ± 316.10. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $4679 vs $4317). Even though most of the patients were females, but 
they had overall lower costs compared to males (amount charged $4513 vs $4582, 
p> 0.05; co-payment $79 vs $106, p< 0.05). Patients who received treatment in the 
Midwest region of the USA had a higher costs compared to east, west and south 
regions (paid amount $4618 vs $4608 vs $4370 vs $4405). ConClusions: The cost 
of Fingolimod treatment for RRMS patients is higher and costing the health plan 
around $3552 for 3 months. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
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objeCtives: Fingolimod is an orally available immune-modulatory drug for treat-
ing relapsing-remitting Multiple Sclerosis (RRMS). It was approved by the European 
Medicines Agency (EMA) in March 2011. Some urgent safety warnings (e.g. progres-
sive multifocal leukoencephalopathy (PML) and cardiovascular events) have been 
reported in the meantime. Early benefit assessment by the Federal Joint Committee 
(G-BA) in 2012 and 2013 showed only additional benefit for a certain subgroup of 
patients. Therefore the use of Fingolimod has widely been discussed in Germany. 
We analyzed prescriptions of Fingolimod and the impact of Health Technology 
Assessment (HTA) and drug safety warnings. Methods: We used routine data of 
the Techniker Krankenkasse (TK), a large German sickness fund with more than 
8.2 million insured, from 2012 to 2014. We looked for prescriptions of disease-
modifying therapies (DMT) for patients with Multiple Sclerosis (MS). Diagnosis of 
MS was identified by G35 according to ICD-10. Considered DMT were Fingolimod, 
Glatiramer Acetate, Alemtuzumab, Natalizumab, Interferon beta-1a, Interferon beta-
between treatment groups. Differences reflected the known efficacy and safety 
profile of BRV. Where reported for other AEDs, changes from baseline and treatment 
group differences are similarly small, raising questions about the appropriateness of 
short-term fixed-dose trials as a source of HRQoL data for adjunctive AEDs in refrac-
tory patients. Long-term assessments may be more informative. Supported by UCB.
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objeCtives: The aim of this paper is to analyze pharmaceutical expenditure in 
Alzheimer patients from a Europe southeastern region (Valencian Region (Spain)), 
by using the clustering patients system Clinical Risk Group (CRGs). We focused on 
obtaining more information about Alzheimer patients, stablishing a more accurate 
prediction of their resources consumption and individuating patterns of pharma-
ceutical consumption. Methods: A cross-sectional study of the inhabitants of 
Valencian region with a population of 5,000,000 was carried out, using data extracted 
from Electronic Health Records for 2013. A sample of 24641 Alzheimer individuals 
were identified. Results: From our sample 29.4% men and 70.6% women were 
found. The annual average cost per Alzheimer patient is € 1709.051. By gender, 
women average cost is 1718,66 € while men average consumption is 1685,97 € . Age 
is the variable which most affect pharmaceutical cost variability, while severity 
levels are not capable to explain cost variability. ConClusions: Valuable informa-
tion about pharmaceutical cost of Alzheimer patients was found. In contradiction 
to other diseases, for the Alzheimer case, levels of severity does not provide a clear 
explanation of pharmaceutical cost variability.
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objeCtives: Transition from RRMS to SPMS is difficult to diagnose. Here, we describe 
methodology for developing a screening tool that can help physicians to diagnose 
SPMS early. Methods: Tool will be developed along 3 steps: Quantitative research: A 
retrospective cross-sectional study to describe differentiating characteristics between 
SPMS and late RRMS patients using Adelphi Real World database. 2791 MS patient 
record forms from 125 neurologists (US) are available. Key variables will include demo-
graphics, MS history, treatment history, daily activities, symptoms and clinical charac-
teristics including MRI activity. Patients will be stratified based on EDSS and disease 
duration into: Early RRMS (control group), Late RRMS and Early SPMS. A multivariate 
regression analysis will identify the significant predictors of patient classification 
as ‘Late RRMS’ or ‘Early SPMS’ by physician. Qualitative research: (1) Open-ended 
qualitative interviews of patients (16 each in the US and Germany—8 RRMS and 8 
SPMS/country) and treating clinicians (8/country) to identify and characterize key 
differentiating features of these two MS phenotypes. (2) Integrating interviews with 
quantitative research to draft the tool. (3) Use of draft version by physicians treating 
SPMS patients. (4) Cognitive debriefing with physician. Tool validation: Sensitivity 
and specificity will be validated against reference tests in a 12Month prospective 
observational study in patients with late RRMS and SPMS after the implementation of 
the tool. Results: Data collected will be used to generate a paper version of the tool 
that will track the disease experience of late RRMS patients periodically (relapse and 
recovery, symptoms, quality of life). After validating the paper version, an electronic 
version will be considered. A calculator will be added to the tool to predict likelihood 
of patient progression to SPMS. ConClusions: Such a validated tool is expected to 
support physicians in more accurate and timely identification of SPMS patients to 
provide optimized clinical intervention.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is charac-
terised by enlarged kidneys, declining renal function and ultimately progression 
towards end-stage renal disease (ESRD), with significant mortality, co-morbidity 
and resource implications. This study aimed to quantify the humanistic and health 
system burden of ADPKD in the UK, and the potential impact of ADPKD treatment 
that may delay progression to ESRD. Methods: ADPKD progression was predicted 
over a 50-year horizon using the ADPKD Outcomes Model. Patient profiles consistent 
with the CRISP longitudinal ADPKD outcomes trial were modelled using regression 
equations for renal decline derived from the TEMPO 3:4 study placebo arm. ESRD 
rates were drawn from UK published sources. Treatment-related reduction in the 
rate of renal decline was based on TEMPO 3:4 (tolvaptan: 31.6%). ESRD outcomes, 
quality-adjusted life-years (QALYs) and life-years accumulated were reported per 
1,000 patients, and scaled to the UK population. Results: Without treatment, 927 
incident ESRD events were predicted per 1,000 patients; corresponding to 372 inci-
dent transplants, 435 dialysis access procedures and 4,707 dialysis years. Treatment 
was estimated to prevent 61 ESRD events per 1,000 patients, thereby avoiding 82 
transplants, 39 access procedures and 707 dialysis years, and accruing an additional 
2,788 QALYs and 3,075 life-years (undiscounted). Delay of ESRD beyond retirement 
age (65 years) was predicted in 16.6% of treated patients with 3,356 additional work-
